Jasper Therapeutics (NASDAQ:JSPR) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Jasper Therapeutics (NASDAQ:JSPR) announced its quarterly earnings results on Thursday. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.08, Zacks reports.

Jasper Therapeutics Stock Up 4.2%

NASDAQ:JSPR traded up $0.04 during trading hours on Thursday, hitting $0.96. 180,431 shares of the company’s stock traded hands, compared to its average volume of 553,856. The firm has a market cap of $26.85 million, a P/E ratio of -0.21 and a beta of 3.07. Jasper Therapeutics has a 52 week low of $0.62 and a 52 week high of $7.19. The business’s fifty day simple moving average is $1.02 and its two-hundred day simple moving average is $1.45.

Institutional Investors Weigh In On Jasper Therapeutics

Several large investors have recently added to or reduced their stakes in JSPR. Engineers Gate Manager LP bought a new stake in Jasper Therapeutics during the fourth quarter worth about $26,000. Panagora Asset Management Inc. bought a new stake in Jasper Therapeutics during the fourth quarter worth about $35,000. Acadian Asset Management LLC bought a new stake in Jasper Therapeutics during the first quarter worth about $46,000. Voleon Capital Management LP bought a new stake in Jasper Therapeutics during the third quarter worth about $50,000. Finally, Jain Global LLC bought a new stake in Jasper Therapeutics during the fourth quarter worth about $79,000. Institutional investors own 79.85% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on JSPR shares. UBS Group started coverage on Jasper Therapeutics in a research report on Monday, March 23rd. They issued a “neutral” rating for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Tuesday, April 21st. Six investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $19.88.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.